Bayer (BAYN GY) announces that results from the Phase III FIND-CKD trial investigating KERENDIA in adults with nd-CKD met the primary endpoint by showing a significant reduction in the rate of kidney disease progression
#GERMANY#UNITED KINGDOM#EUROPE#BAYER AG#BAYN.GY#3I GROUP PLC#EQUITIES#EU SESSION#PHARMACEUTICALS#ASSET MANAGEMENT & CUSTODY BANKS#PHARMACEUTICALS (GROUP)#CAPITAL MARKETS#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#FINANCIAL SERVICES#BAYN#EURO STOXX 50#DAX 40 INDEX#FTSE 100 INDEX#III